COMP <GO>
AUPH vs PRGO // 10Y YIELD & FRED MACRO BETA
Aurinia Pharmaceuticals Inc (NASDAQ) VS. Perrigo Company plc (NYSE) • 15-METRIC TALLY: AUPH 8
— PRGO 3
■ METRIC PARITY
LAST: $16.14 (-3.06%) • MKT CAP: $2.22B
macro-sensitivity
—
LAST: $15.75 (-0.19%) • MKT CAP: $2.19B
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AUPH VS. PRGO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AUPH | PRGO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 35.10% | +53.40 | AUPH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.50% | -13.60% | +30.10 | AUPH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.1x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.92% | 6.58% | -0.66 | PRGO | /fcf-yield <GO> |
| Operating Margin | 37.10% | -26.40% | +63.50 | AUPH | /operating-margins <GO> |
| Net Profit Margin | 68.00% | -33.50% | +101.50 | AUPH | /net-margins <GO> |
| Revenue Growth (YoY) | 20.40% | -2.80% | +23.20 | AUPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 7.22% | -7.22 | PRGO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.33 | 0.20 | +8.13 | AUPH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 5/9 | +2.00 | AUPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.1 | 54.8 | -5.70 | PRGO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.7x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.22B | $2.19B | $25.5M | AUPH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AUPH REV | PRGO REV | AUPH GROSS % | PRGO GROSS % | AUPH FCF | PRGO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $283.1M | $4.25B | 88.5% | 35.1% | $135.7M | $145.1M |
| FY 2024 | $235.1M | $4.37B | 88.0% | 35.3% | $44.4M | $244.6M |
| FY 2023 | $175.5M | $4.66B | — | — | -$33.5M | $405.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AUPH // BETA —
PRGO // BETA —